Retesting Semaglutide: following up on last cycle's discrepancies
Purity across our Semaglutide samples ranged from 58.1% to 99.1%. Here is the context.
The Peptide Institute Testing Desk··8 min read
Semaglutide is a glp-1 receptor agonist with a development status of "fda-approved (branded forms)". The Institute rates the strength of its published evidence as strong. A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, supported by large randomized controlled trials.
This report covers the Semaglutide samples processed in our most recent testing cycle. Every specimen was purchased anonymously at retail, transferred under chain-of-custody documentation, and analysed by an independent contract laboratory.
The Institute has independently tested 23 Semaglutide samples from 13 companies. 87% met their label claims on purity and content. Measured purity ranged from 58.1% to 99.1%, averaging 95.5%. 1 sample failed verification outright. Every specimen is published in full, including the laboratory that ran it.
The Peptide Institute is an independent research institute. We do not sell products, we do not accept vendor sponsorship, and we publish results that reflect badly on companies as readily as results that do not.
Purity across our Retatrutide samples ranged from 58.2% to 99.7%. Here is the context.
Study Summary
Free download
Get the free Peptide Playbook, plus new breakthroughs as they happen.
What peptides are, why people are using them, and what results people are talking about,
in plain English. Sign up and we email you the Playbook right away.
